Gain Therapeutics Inc
NASDAQ:GANX
Gain Therapeutics Inc
NASDAQ:GANX
Price:
2.9 USD
1.75%
Market Closed
Updated:
May 8, 2024
Gain Therapeutics Inc
Cash from Operating Activities
|
Gain Therapeutics Inc
Cash from Operating Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Gain Therapeutics Inc
NASDAQ:GANX
|
Cash from Operating Activities
-$18.9m
|
CAGR 3-Years
-80%
|
CAGR 5-Years
-91%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$8B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$8.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$4.7B
|
CAGR 3-Years
22%
|
CAGR 5-Years
14%
|
CAGR 10-Years
24%
|
See Also
What is Gain Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-18.9m
USD
-18.9m
USD
Based on the financial report for Dec 31, 2023, Gain Therapeutics Inc's Cash from Operating Activities amounts to -18.9m USD.
What is Gain Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-91%
-91%
Over the last year, the Cash from Operating Activities growth was -28%. The average annual Cash from Operating Activities growth rates for Gain Therapeutics Inc have been -80% over the past three years , -91% over the past five years .
You don't have any saved screeners yet
